GLP-1 Medications · AustraliaWhat Eli Lilly's PBS Standoff
Means for Australians on Mounjaro
Lilly walked away from the PBS listing for Mounjaro. Here's a plain-English look at what happened, what it means for your hip pocket, and the practical steps that help when a medication is expensive and entirely self-funded.
MediRemind helps you manage every dose you pay for. 30-day trial, then a subscription.
Already prescribed? Track your injection day, dose and repeats, MediRemind.
Compare what you’d pay for 13 common medications with the PBS cost calculator.
What actually happened
Australia's independent Pharmaceutical Benefits Advisory Committee (PBAC) reviewed Mounjaro and recommended it be listed on the PBS for type 2 diabetes, acknowledging its clinical value. Listing, though, requires the manufacturer to agree to the price and conditions the government sets. That's where it broke down.
Eli Lilly declined to proceed. The company described the government's offer as "unrealistic and unviable," argued it was lower than any comparable health system in the world, and said the recommendation came with funding caps that placed what it considered disproportionate financial risk on Lilly. After several reimbursement submissions across roughly three years, the company concluded it could not list at the terms on the table.
Both sides have a point. The government's job is to get value for taxpayers and keep the PBS sustainable. The manufacturer's job is to price a product across many markets without setting a precedent it can't sustain. While both hold their positions, it's patients who carry the cost.
For an estimated 450,000 Australians living with type 2 diabetes, subsidised access just got more uncertain. And for the many more using tirzepatide for weight management, where it has not been PBS-subsidised, the broader signal that affordable access remains distant is the part that stings.
What it means for your costs
The immediate practical reality: Mounjaro remains a private, out-of-pocket medicine. Published pharmacy examples checked on 1 October 2026 ranged from $279.99 to $689.99 for one KwikPen containing four weekly doses, before any consultation, dispensing or delivery fees.
When a medicine costs several hundred dollars a month, the stakes around managing it well go up sharply. A dosing delay, a script that expires unnoticed, or an empty supply before you can get to the pharmacy isn't just inconvenient. It's money and momentum lost on a treatment you're funding yourself.
Prices vary between pharmacies. Use the MediRemind PBS cost calculator to estimate your exact out-of-pocket cost for Mounjaro, Ozempic, or Wegovy.
Mounjaro price in Australia by dose (2026)
Mounjaro is not PBS-listed for any use, so every dose level is a private script. Prices below are published Chemist Warehouse examples checked on 1 October 2026. Confirm the current price and availability with your pharmacy.
Mounjaro 2.5mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $279.99 for one KwikPen containing four weekly doses.
Mounjaro 5mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $389.99 for one four-dose KwikPen. Other pharmacies may list a different price.
Mounjaro 7.5mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $539.99 for one four-dose KwikPen.
Mounjaro 10mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $539.99 for one four-dose KwikPen.
Mounjaro 12.5mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $689.99 for one four-dose KwikPen.
Mounjaro 15mg price Australia
A published Chemist Warehouse example checked on 1 October 2026 was $689.99 for one four-dose KwikPen.
At these prices, an expired script or a wasted dose is expensive. MediRemind tracks your current dose level, weekly injection day and remaining repeats. Start your 30-day trial, then a subscription.
Practical ways to protect an expensive, self-funded medication
None of this is medical advice. Always talk to your doctor or pharmacist about your treatment. But on the logistics of staying on track, a few habits make a real difference, especially with a weekly injectable like Mounjaro:
Treat your script like the valuable thing it is
Know exactly how many repeats you have left and when each one expires, so you can plan ahead and avoid letting a paid script lapse unused. One expired repeat on a $400/month medication is real money gone.
Set the weekly reminder and make it stick
GLP-1 medicines like Mounjaro are taken once a week, which is surprisingly easy to lose track of compared to a daily tablet. A reminder that nudges you on the same day each week, and keeps nudging until you confirm, protects both your routine and your spend.
Plan refills ahead of supply gaps
These medicines have had well-publicised supply pressures in Australia. Knowing your repeat is running low before you're down to your last pen gives you time to sort it out rather than scrambling.
Keep the whole picture in one place
If you're managing other medications too, or helping a partner or parent with theirs, having every script, repeat and reminder in a single view makes an expensive, complex regimen far easier to stay on top of.
MediRemind is an Australian-made app that keeps your eScripts, paper scripts, repeats and reminders together in one place, with persistent reminders (including for weekly injections) and a separate profile for each family member. It can't change what a medicine costs, but it can help make sure that not a single dose you've paid for goes to waste.
The bigger conversation
Standoffs like this one are a reminder that access to medicines in Australia isn't only about whether a drug works. It's about the negotiation between government and industry over what we'll collectively pay. Those conversations will continue, and the PBS outcome for these medicines may yet change. In the meantime, the most useful thing any of us can do is manage the medications we have as carefully as possible.
Frequently asked questions
Is Mounjaro listed on the PBS in Australia?
No. As of 1 October 2026, Mounjaro (tirzepatide) is not listed on the Pharmaceutical Benefits Scheme. PBS status records show that one March 2026 submission was discontinued at the sponsor's request; an earlier submission's listing arrangements had not commenced as of 1 October 2026. Neither record shows a PBS listing. It remains a private, out-of-pocket medicine.
How much does Mounjaro cost in Australia without PBS?
Published pharmacy examples checked on 1 October 2026 ranged from $279.99 for the 2.5mg KwikPen to $689.99 for the 12.5mg and 15mg KwikPens. Each KwikPen contains four weekly doses; prices vary by pharmacy and may change.
Can I get Mounjaro subsidised in Australia?
Mounjaro is not PBS-listed for any use. Some private health insurance extras may cover part of the cost for some patients; check with your insurer.
Will Mounjaro ever be listed on the PBS?
The future is uncertain. PBS records show different stages for separate tirzepatide submissions: one March 2026 submission was discontinued at the sponsor's request, while an earlier submission's listing arrangements had not commenced as of 1 October 2026. No PBS listing is shown. Any future listing would depend on the official process and agreement on listing arrangements.
How can MediRemind help me manage Mounjaro costs?
MediRemind tracks your eScripts and repeat prescriptions so you always know how many repeats remain and when they expire. It sends weekly injection reminders and alerts you before your repeats are exhausted, helping make sure not a single dose you've paid for goes to waste.
How much is Mounjaro at Chemist Warehouse?
Published Chemist Warehouse examples checked on 1 October 2026 were $279.99 for 2.5mg, $389.99 for 5mg, $539.99 for 7.5mg and 10mg, and $689.99 for 12.5mg and 15mg. Prices and availability change, so confirm the current amount before dispensing.
How much is Mounjaro compared to Ozempic or Wegovy on the PBS in Australia?
Mounjaro is not PBS-listed for any use, so patients pay the private price. Published pharmacy examples checked on 1 October 2026 ranged from $279.99 to $689.99 for a four-week KwikPen. Ozempic is PBS-listed for eligible type 2 diabetes patients, while Wegovy is not currently PBS-listed. Use the PBS cost calculator at https://www.mediremind.com.au/pbs-medication-cost-calculator-australia to compare current PBS and private prices.
How do I find out exactly what my medication will cost?
Use the MediRemind PBS cost calculator at https://www.mediremind.com.au/pbs-medication-cost-calculator-australia. Enter your medication name and it shows the current PBS co-payment, private prescription price, concession rate, and Safety Net threshold.
References to weight management medications on this page are for general information only. MediRemind does not prescribe, supply or endorse any specific medication. Individual circumstances vary, speak to your doctor about which treatment is appropriate for you.
Make sure every dose you pay for counts.
Track your Mounjaro injection day, prescribed dose and repeats with MediRemind. 30-day trial, then a subscription. $4.99/month or $39.99/year.